Good try pump dude Joe. U get paid nickel for a post.
Anybody investing in this mgmt esp considering their track record may as well flush the money down the toilet
Urge the gambler longs here to ask this question in the next investor preso
Raj was also confident that fusilev will grow back in 2012
Raj was also confident that easing of generic leucvorin shortage will not impact fusilev sales in 2012
Raj was also confident to double folotyn sales in a few year since 2012
Raj was also confident zevalin would be $300m drug in a "few" years....since 2010
You get paid to pump.
You cannot respond to any of the hypes that are proven hypes from management ....hypes that are till today not reality.
The hypes of management on drug sales have remained hypes
So no word on spi2012 can be trusted. Imho
Why don't you like the facts? Hype is hype
Hype equals big loss for suckers who believe in those statements
Thank you for at least shedding some light on fusilev guidance in 2012 and the managements abysmal record on that guidance.
Now this is not a one off. Please see their hype or forward looking guidance on other drugs. Everything can be heard in investor presentations from 2011 2012 2013. Way off on zevalin. Way off on folotyn ...pump on apaz after p3 failure..
Hence hype vs reality very much in favor of hype.
So I conclude spi2012 could be hype
Stand corrected. Blockbuster 8 cent decrease on blockbuster announcement on a potential blockbuster drug.
Blockbuster hopes of cavejoetartiasherry
Where is the top line data
How does efficacy and safety data compare with brand
Why no talk of secondary end point. Did it fail that end point?
Joe correct me if I am wrong on anything I said.
Hype vs reality record is pathetically tilted in favor of hype.
Why was no top line data released for sppi2012 and no secondary end points
Ist it was fusilev growth hype which failed in March 2013
Then zevalin could do $300m in a few years hype surfaced in 2010 2011
Then folotyn we could double its sales if we treat mucositis using fusilev hype started in 2012 2013
Then apaziquone could still receive fda approval if we change the trial criteria hype started in 2012 2013
Now the 2014 hype is surrounding spi2012 and this drug for gods sake has Not yet passed p2 and years away from approval even if everything goes its way.
Some desperate and unethical frustrated longs are saying fda will approve without p3. Another f in hype.
Beware investors. Judge the mgmt based on past statements and the reality of those statements
Stop wasting everyone's time on spi2012 by hyping a drug whose p1 data is known
Huge risk ahead....clinical, regulatory, commercialization, competition risks.
Yet Joe and his 10k ids keep hyping
Sentiment: Strong Sell